Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 13, 2016 9:30 AM - Nov 15, 2016 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

[V2-S3] Medical Affairs Activities from the Viewpoint of the Stakeholder

Session Chair(s)

Kihito  Takahashi

Kihito Takahashi

Partner

Mirasense Partners, Japan

Medical Affairs has various responsibilities, including information activities performed in pursuit of “Launch Excellence” during the development, application for approval, approval, and launch process of a drug, building medical strategies, engaging with key opinion leaders, and responding to drug-related inquiries. These medical activities are separate from promotion and independent of marketing, but the role of Medical Affairs is not yet widely recognized in Japan, or even within the pharmaceutical industry. This session will provide expert lectures on the role and duties of Medical Affairs, including Launch Excellence activities and support of investigator-initiated clinical trials, what different stakeholders expect from them, and what issues may arise.

Speaker(s)

Kyoko  Murakami, MD, PhD

The Activity of MA and the Role of Medical Doctor in a Pharmaceutical Company

Kyoko Murakami, MD, PhD

GlaxoSmithKline K.K., Japan

Associate Department Manager, MA Immuno-Inflammation & Infectious Diseases Dept.

Masuhiro  Kato, PhD

The Expectations and Current Issues Surrounding MA Regarding Investigator Initiated Trials

Masuhiro Kato, PhD

The University of Tokyo Hosptial, Japan

Project Professor, Translational Research Initiative

Ikuo  Miyamoto, MSc, MT, RPh

Expectations and Current Issues Surrounding MA

Ikuo Miyamoto, MSc, MT, RPh

Japan Pharmaceutical Manufacturers Association (JPMA), Japan

Taskforce Leader, PMS Department

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.